Addex Therapeutics Ltd

NasdaqCM ADXN

Addex Therapeutics Ltd Price to Sales Ratio (P/S) on December 30, 2024: 13.87

Addex Therapeutics Ltd Price to Sales Ratio (P/S) is 13.87 on December 30, 2024, a 241.24% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Addex Therapeutics Ltd 52-week high Price to Sales Ratio (P/S) is 19.46 on October 24, 2024, which is 40.29% above the current Price to Sales Ratio (P/S).
Addex Therapeutics Ltd 52-week low Price to Sales Ratio (P/S) is 3.90 on January 17, 2024, which is -71.91% below the current Price to Sales Ratio (P/S).
Addex Therapeutics Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 10.30.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ADXN

Addex Therapeutics Ltd

CEO	Mr. Timothy Mark Dyer
IPO Date	Feb. 12, 2020
Location	Switzerland
Headquarters	Chemin des Mines, 9
Employees	23
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Key trends

Past 5 years